TGFB1 and type 1 diabetes mellitus: In conclusion, oral administration of ATRA/TGF-β MPs ameliorated T1D by enhancing tolerogenic dendritic cells (tolDCs) and Tregs, suppressing Th1 responses, and preventing immune cells from entering islets (46).